Cenra Inc.

TWSE:1701 Lagerbericht

Marktkapitalisierung: NT$6.0b

Cenra Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Cenra.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum48.0%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50

Jul 12
China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50

Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching

Apr 25
Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching

We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt

Apr 07
We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt

The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On

Mar 17
The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On

China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Feb 24
China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?

Jan 27
Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?

Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?

Jan 06
Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?

The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On

Dec 16
The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On

China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 26
China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Cenra jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

TWSE:1701 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/20248,871355317636N/A
3/31/20248,762328258571N/A
12/31/20238,575322340602N/A
9/30/20238,619317217487N/A
6/30/20238,599387301585N/A
3/31/20238,572489216485N/A
12/31/20228,457478-96167N/A
9/30/20228,147526-21642N/A
6/30/20227,98152850277N/A
3/31/20227,936477291522N/A
12/31/20217,949518488696N/A
9/30/20218,102459785999N/A
6/30/20218,211448596833N/A
3/31/20218,088574468707N/A
12/31/20208,181557625897N/A
9/30/20208,061531365658N/A
6/30/20208,006512425738N/A
3/31/20208,07541279603N/A
12/31/20197,970385-165328N/A
9/30/20197,630360-42367N/A
6/30/20197,669368-40338N/A
3/31/20197,547343-300-78N/A
12/31/20187,580370-64153N/A
9/30/20187,562374140321N/A
6/30/20187,083372188354N/A
3/31/20186,714326N/A449N/A
12/31/20176,245311N/A462N/A
9/30/20175,988293N/A419N/A
6/30/20175,848257N/A397N/A
3/31/20175,822305N/A471N/A
12/31/20165,781313N/A194N/A
9/30/20165,785311N/A383N/A
6/30/20165,771362N/A447N/A
3/31/20165,717352N/A421N/A
12/31/20155,628354N/A555N/A
9/30/20155,568450N/A378N/A
6/30/20155,471395N/A254N/A
3/31/20155,350384N/A224N/A
12/31/20145,297348N/A330N/A
9/30/20145,257253N/A441N/A
6/30/20145,274260N/A641N/A
3/31/20145,271266N/A581N/A
12/31/20135,174240N/A405N/A
9/30/20135,125256N/A471N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 1701's forecast earnings growth is above the savings rate (1%).

Ertrag vs. Markt: Insufficient data to determine if 1701's earnings are forecast to grow faster than the TW market

Hohe Wachstumserträge: Insufficient data to determine if 1701's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 1701's revenue is forecast to grow faster than the TW market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 1701's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 1701's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y